Lyell Immunopharma (LYEL) Non Operating Income (2021 - 2026)

Lyell Immunopharma has reported Non Operating Income for 6 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Non Operating Income fell 57.58% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 53.43% YoY) and the FY2025 annual result came in at $13.1 million, down 17.01% from the prior year.
• Non Operating Income fell to $2.2 million in Q1 2026 per LYEL's latest filing, from $2.7 million in the prior quarter.
• Over five years, Non Operating Income peaked at $6.6 million in Q3 2023 and troughed at -$5.1 million in Q1 2024.
• A 5-year average of $2.5 million and a median of $3.3 million in 2025 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 1351.59% in 2022, down 1434.62% in 2022.
• Over 5 years, Non Operating Income stood at $6.4 million in 2022, then rose by 2.99% to $6.6 million in 2023, then sank by 151.49% to -$3.4 million in 2024, then surged by 179.01% to $2.7 million in 2025, then fell by 18.01% to $2.2 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.2 million, $2.7 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.